Clinical Trial Detail

NCT ID NCT01953692
Title A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

bone marrow cancer

multiple myeloma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.